# Multimodality Phase II Study in Prostate Cancer

> **NCT00734851** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 36 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Sunitinib
- **RADIATION:** EBXRT

## Key facts

- **NCT ID:** NCT00734851
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2014-09
- **Final completion:** 2014-11
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Dose Limiting Toxicities
- **Last updated:** 2015-12-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00734851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00734851, "Multimodality Phase II Study in Prostate Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00734851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*